Puma Biotechnology (PBYI) Net Income towards Common Stockholders (2010 - 2026)
Puma Biotechnology (PBYI) posted Net Income towards Common Stockholders of -$3.8 million for Q1 2026, down 122.26% on a QoQ basis from $16.9 million in Q4 2025, and down 226.19% year-over-year from $3.0 million in Q1 2025.
Puma Biotechnology (PBYI) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Puma Biotechnology's Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$3.8 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 226.19% year-over-year to -$3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.8 million (up 265.22% YoY) and the FY2025 annual result came in at $34.5 million, up 19834.29% from the prior year.
- Net Income towards Common Stockholders was -$3.8 million for Q1 2026 at Puma Biotechnology, down from $16.9 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $20.3 million in Q3 2024 and bottomed at -$11.1 million in Q4 2024.
- A 5-year average of $3.1 million and a median of $2.1 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders surged 1710.0% — and 2024, when it sank 443.68%.
- Puma Biotechnology's Net Income towards Common Stockholders stood at -$5.2 million in 2022, then soared by 341.62% to $12.4 million in 2023, then slumped by 189.57% to -$11.1 million in 2024, then soared by 251.26% to $16.9 million in 2025, then slumped by 122.26% to -$3.8 million in 2026.
- Business Quant data shows PBYI's Net Income towards Common Stockholders at -$3.8 million in Q1 2026, $16.9 million in Q4 2025, and $8.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -0.68 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 366.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Puma Biotechnology | 406.51 Mn | 368.22 Mn | 34.39 Mn | -3.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.75 Mn |
| Dec 31, 2025 | 16.86 Mn |
| Sep 30, 2025 | 8.84 Mn |
| Jun 30, 2025 | 5.86 Mn |
| Mar 31, 2025 | 2.97 Mn |
| Dec 31, 2024 | -11.15 Mn |
| Sep 30, 2024 | 20.32 Mn |
| Jun 30, 2024 | -4.53 Mn |
| Mar 31, 2024 | -4.82 Mn |
| Dec 31, 2023 | 12.45 Mn |
| Sep 30, 2023 | 5.80 Mn |
| Jun 30, 2023 | 2.13 Mn |
| Mar 31, 2023 | 1.40 Mn |
| Dec 31, 2022 | -5.15 Mn |
| Sep 30, 2022 | -360,000.00 |
| Jun 30, 2022 | 9.37 Mn |
| Mar 31, 2022 | -3.40 Mn |
| Dec 31, 2021 | 4.22 Mn |
| Sep 30, 2021 | -44.67 Mn |
| Jun 30, 2021 | -5.11 Mn |